GEN Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024

Company Announcement

  • Net sales of DARZALEX® in the third quarter of 2024 totaled USD 3,016 million
  • Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen)

COPENHAGEN, Denmark; October 15, 2024 – (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were USD 3,016 million in the third quarter of 2024. Net trade sales were USD 1,684 million in the U.S. and USD 1,332 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to Janssen to develop, manufacture and commercialize daratumumab.  

About Genmab 

Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO®) antibody medicines. 

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit  and follow us on and .





Contact:        

Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs

T: ; E:

Andrew Carlsen, Vice President, Head of Investor Relations

T: ; E:



This Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at . Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.



Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®. DARZALEX® and DARZALEX FASPRO® are trademarks of Johnson & Johnson.

Company Announcement no. 59

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Carl Jacobsens Vej 30

2500 Valby

Denmark

Attachment



EN
15/10/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Genmab A/S

Rune Majlund Dahl
  • Rune Majlund Dahl

Genmab (Buy, TP: DKK2500.00) - Still awaiting CD-38 decision

Q3 revenue missed our expectations, but operating profit exceeded due to lower operating costs. 2024 guidance for revenue was raised to DKK21.1bn–21.7bn; for opex was narrowed downwards to DKK14.1bn–14.4bn (due to portfolio prioritisation); and for operating profit, narrowed to the high end of DKK6.2bn–7.1bn. Investor focus was on JNJ’s upcoming opt-in decision (data submission expected end-2024). We reiterate our BUY and DKK2,500 target price.

 PRESS RELEASE

Genmab Announces Financial Results for the First Nine Months of 2024

Genmab Announces Financial Results for the First Nine Months of 2024 November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024 Highlights European Commission (EC) granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapyGenmab announced that it will assume sole responsibility for the continued development and potential commercialization of acasunlimabGenmab revenue increased 29% com...

 PRESS RELEASE

Genmab to Present at Jefferies London Healthcare Conference

Genmab to Present at Jefferies London Healthcare Conference Media ReleaseCOPENHAGEN, Denmark; November 5, 2024 (Nasdaq: GMAB) announced today that its Chief Executive Officer, Jan van de Winkel, Ph.D. and Chief Financial Officer, Anthony Pagano will take part in a fireside chat at the Jefferies London Healthcare Conference on November 19, 2024 at 4:30 PM CET / 10:30 AM EST. A webcast of the event will be available on Genmab’s website at . About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving...

 PRESS RELEASE

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-b...

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting Media ReleaseCOPENHAGEN, Denmark; November 5, 2024 More than 20 abstracts, including four oral presentations, with new clinical data across lines of therapy and subgroups of non-Hodgkin’s lymphoma (NHL) patientsNew and updated data from EPCORE® clinical trial program reinforce the potential of epcoritamab as a monotherapy and in combination to treat multiple B-cell malignancies across lines of therapy (Nasdaq: GMAB) announced today more...

 PRESS RELEASE

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarte...

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024 Company Announcement Net sales of DARZALEX® in the third quarter of 2024 totaled USD 3,016 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; October 15, 2024 – (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were USD 3,016 millio...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch